Cell therapy weekly: Kymriah® satisfies primary trial endpoint at interim analysis of Phase II follicular lymphoma study

Written by RegMedNet

This week: Avacta Group (Leeds, UK) announces its expanded collaboration with Daewoong Pharmaceutical (Seoul, South Korea), Brooks Life Sciences (MA, USA) has announced the launch of a next-generation, liquid nitrogen-based storage system and researchers observe specialized neural stem cell grafts to form functional synaptic connections with host neurons at spinal cord injury sites in mice. The news highlights: Kymriah® satisfies primary endpoint at interim analysis of global follicular lymphoma trial data Collaboration expanded to develop potential stem cell therapies for lung damage due to severe COVID-19 Next-generation, liquid nitrogen-based storage system launched Neural stem cell grafts appear to integrate with...

To view the full article, please register now for access

It's completely free